RESUMEN
Erythrina velutina is a species of arboreal leguminous that occurs spontaneously in the northeastern states of Brazil. Leguminous seeds represent an abundant source of peptidase inhibitors, which play an important role in controlling peptidases involved in essential biological processes. The aim of this study was to purify and characterize a novel Kunitz-type peptidase inhibitor from Erythrina velutina seeds and evaluate its anti-proliferative effects against cancer cell lines. The Kunitz-type chymotrypsin inhibitor was purified from Erythrina velutina seeds (EvCI) by ammonium sulphate fractionation, trypsin- and chymotrypsin-sepharose affinity chromatographies and Resource Q anion-exchange column. The purified EvCI has a molecular mass of 18 kDa with homology to a Kunitz-type inhibitor. Inhibition assays revealed that EvCI is a competitive inhibitor of chymotrypsin (with K i of 4 × 10-8 M), with weak inhibitory activity against human elastase and without inhibition against trypsin, elastase, bromelain or papain. In addition, the inhibitory activity of EvCI was stable over a wide range of pH and temperature. Disulfide bridges are involved in stabilization of the reactive site in EvCI, since the reduction of disulfide bridges with DTT 100 mM abolished ~ 50% of its inhibitory activity. The inhibitor exhibited selective anti-proliferative properties against HeLa cells. The incubation of EvCI with HeLa cells triggered arrest in the cell cycle, suggesting that apoptosis is the mechanism of death induced by the inhibitor. EvCI constitutes an interesting anti-carcinogenic candidate for conventional cervical cancer treatments employed currently. The EvCI cytostatic effect on Hela cells indicates a promised compound to be used as anti-carcinogenic complement for conventional cervical treatments employed currently.
RESUMEN
BACKGROUND: Garcinia brasiliensis is a species native to the Amazon forest. The white mucilaginous pulp is used in folk medicine as a wound healing agent and for peptic ulcer, urinary, and tumor disease treatments. The activity of the proprotein convertases (PCs) Subtilisin/Kex is associated with the development of viral, bacterial and fungal infections, osteoporosis, hyperglycemia, atherosclerosis, cardiovascular, neurodegenerative and neoplastic diseases. METHODS: Morelloflavone (BF1) and semisynthetic biflavonoid (BF2, 3 and 4) from Garcinia brasiliensis were tested as inhibitor of PCs Kex2, PC1/3 and Furin, and determined IC50, Ki, human proinflammatory cytokines secretion in Caco-2 cells, mechanism of inhibition, and performed molecular docking studies. RESULTS: Biflavonoids were more effective in the inhibition of neuroendocrine PC1/3 than mammalian Furin and fungal Kex2. BF1 presented a mixed inhibition mechanism for Kex2 and PC1, and competitive inhibition for Furin. BF4 has no good interaction with Kex2 and Furin since carboxypropyl groups results in steric hindrance to ligand-protein interactions. Carboxypropyl groups of BF4 promote steric hindrance with Kex2 and Furin, but effective in the affinity of PC1/3. BF4 was more efficient at inhibiting PCl/3 (IC50 = 1.13 µM and Ki = 0,59 µM, simple linear competitive mechanism of inhibition) than Kex2, Furin. Also, our results strongly suggested that BF4 also inhibits the endogenous cellular PC1/3 activity in Caco-2 cells, since PC1/3 inhibition by BF4 causes a large increase in IL-8 and IL-1ß secretion in Caco-2 cells. CONCLUSIONS: BF4 is a potent and selective inhibitor of PC1/3. GENERAL SIGNIFICANCE: BF4 is the best candidate for further clinical studies on inhibition of PC1/3.
Asunto(s)
Biflavonoides , Células CACO-2 , Furina , Humanos , Simulación del Acoplamiento MolecularRESUMEN
Quinolones and fluoroquinolones are widely used to treat uropathogenic Escherichia coli infections. Bacterial resistance to these antimicrobials primarily involves mutations in gyrA and parC genes. To date, no studies have examined the potential relationship between biochemical characteristics and quinolone resistance in uropathogenic E. coli strains. The present work analyzed the quinolone sensitivity and biochemical activities of fifty-eight lactose-negative uropathogenic E. coli strains. A high percentage of the isolates (48.3%) was found to be resistant to at least one of the tested quinolones, and DNA sequencing revealed quinolone resistant determining region gyrA and parC mutations in the multi-resistant isolates. Statistical analyses suggested that the lack of ornithine decarboxylase (ODC) activity is correlated with quinolone resistance. Despite the low number of isolates examined, this is the first study correlating these characteristics in lactose-negative E. coli isolates.
Asunto(s)
Farmacorresistencia Bacteriana Múltiple/genética , Infecciones por Escherichia coli/tratamiento farmacológico , Fluoroquinolonas/uso terapéutico , Lactosa/metabolismo , Ácido Nalidíxico/uso terapéutico , Ornitina Descarboxilasa/genética , Infecciones Urinarias/tratamiento farmacológico , Escherichia coli Uropatógena/genética , Antibacterianos/uso terapéutico , Brasil , Girasa de ADN/genética , Topoisomerasa de ADN IV/genética , Descarboxilación/genética , Descarboxilación/fisiología , Infecciones por Escherichia coli/microbiología , Humanos , Pruebas de Sensibilidad Microbiana , Ornitina/metabolismo , Infecciones Urinarias/microbiología , Escherichia coli Uropatógena/efectos de los fármacos , Escherichia coli Uropatógena/enzimología , Escherichia coli Uropatógena/aislamiento & purificaciónRESUMEN
Quinolones and fluoroquinolones are widely used to treat uropathogenic
Asunto(s)
Humanos , Farmacorresistencia Bacteriana Múltiple/genética , Infecciones por Escherichia coli/tratamiento farmacológico , Fluoroquinolonas/uso terapéutico , Lactosa/metabolismo , Ácido Nalidíxico/uso terapéutico , Ornitina Descarboxilasa/genética , Infecciones Urinarias/tratamiento farmacológico , Escherichia coli Uropatógena/genética , Antibacterianos/uso terapéutico , Brasil , Girasa de ADN/genética , Topoisomerasa de ADN IV/genética , Descarboxilación/genética , Descarboxilación/fisiología , Infecciones por Escherichia coli/microbiología , Pruebas de Sensibilidad Microbiana , Ornitina/metabolismo , Infecciones Urinarias/microbiología , Escherichia coli Uropatógena/efectos de los fármacos , Escherichia coli Uropatógena/enzimología , Escherichia coli Uropatógena/aislamiento & purificaciónRESUMEN
The brown seaweed Spatoglossum schröederi (Dictyotaceae) contains three main fucans (fucans A, B and C) with different mobility in electrophoresis. The fucan with highest mobility (fucan C) was precipitated with 2.0 volumes of acetone, purified using a combination of ion exchange chromatography and electrophoresis. It showed an MW of 24 kDa determined by HPLC and Sephadex G-75 chromatography and migrates as a single band in three distinct electrophoretic systems. This fucan contains fucose, xylose, galactose and sulfate in a molar ratio 1 : 0.6 : 2:2.3. The fucan has neither anticoagulant (from 10 to 100 microg) nor hemorrhagic activities (100 microg/mL). In addition, fucan C is neither cytotoxic nor cytostatic. However, fucan C (100 microg/mL) stimulated the synthesis of an antithrombotic heparan sulfate from endothelial cells of rabbit aorta. The results suggest that fucan C might be used as an antithrombotic therapeutic compound.